PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Maalmi, H.* ; Strom, A.* ; Petrera, A. ; Hauck, S.M. ; Strassburger, K.* ; Kuss, O.* ; Zaharia, O.P.* ; Bönhof, G.J.* ; Rathmann, W.* ; Trenkamp, S.* ; Burkart, V.* ; Szendroedi, J. ; Ziegler, D.* ; Roden, M.* ; Herder, C.*

Serum neurofilament light chain: A novel biomarker for early diabetic sensorimotor polyneuropathy.

Diabetologia 66, 579-589 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Aims/hypothesis: No established blood-based biomarker exists to monitor diabetic sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament light chain (NFL), a blood biomarker of neuroaxonal damage in several neurodegenerative diseases, represents a potential biomarker for DSPN. We hypothesised that higher serum NFL levels are associated with prevalent DSPN and nerve dysfunction in individuals recently diagnosed with diabetes. Methods: This cross-sectional study included 423 adults with type 1 and type 2 diabetes and known diabetes duration of less than 1 year from the prospective observational German Diabetes Study cohort. NFL was measured in serum samples of fasting participants in a multiplex approach using proximity extension assay technology. DSPN was assessed by neurological examination, nerve conduction studies and quantitative sensory testing. Associations of serum NFL with DSPN (defined according to the Toronto Consensus criteria) were estimated using Poisson regression, while multivariable linear and quantile regression models were used to assess associations with nerve function measures. In exploratory analyses, other biomarkers in the multiplex panel were also analysed similarly to NFL. Results: DSPN was found in 16% of the study sample. Serum NFL levels increased with age. After adjustment for age, sex, waist circumference, height, HbA1c, known diabetes duration, diabetes type, cholesterol, eGFR, hypertension, CVD, use of lipid-lowering drugs and use of non-steroidal anti-inflammatory drugs, higher serum NFL levels were associated with DSPN (RR [95% CI] per 1-normalised protein expression increase, 1.92 [1.50, 2.45], p<0.0001), slower motor (all p<0.0001) and sensory (all p≤0.03) nerve conduction velocities, lower sural sensory nerve action potential (p=0.0004) and higher thermal detection threshold to warm stimuli (p=0.023 and p=0.004 for hand and foot, respectively). There was no evidence for associations between other neurological biomarkers and DSPN or nerve function measures. Conclusions/interpretation: Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN. Graphical abstract: [Figure not available: see fulltext.]
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
10.460
2.644
10
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Axonal Damage ; Biomarker ; Demyelination ; Diabetes ; Diabetic Neuropathy ; Diabetic Sensorimotor Polyneuropathy ; Distal Sensorimotor Polyneuropathy ; Electrophysiological Tests ; Large Fibre ; Nerve Conduction Study ; Nerve Dysfunction ; Nerve Injury ; Neurofilament Light Chain ; Neurofilaments ; Neurological Biomarkers ; Peripheral Nervous System ; Peripheral Neuropathy ; Quantitative Sensory Tests ; Small Fibre; Diagnostic-criteria; Nerve-conduction; Definition; Neuropathy; Update
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Zeitschrift Diabetologia
Quellenangaben Band: 66, Heft: 3, Seiten: 579-589 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin ; Heidelberg [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) CF Metabolomics & Proteomics (CF-MPC)
Institute of Diabetes and Cancer (IDC)
POF Topic(s) 30203 - Molecular Targets and Therapies
90000 - German Center for Diabetes Research
Forschungsfeld(er) Enabling and Novel Technologies
Helmholtz Diabetes Center
PSP-Element(e) G-505700-001
G-501900-251
A-630700-001
Förderungen SMH
DZD
German Federal Ministry of Educationand Research (Berlin, Germany
Ministry of Cultureand Science of the state of North Rhine-Westphalia (Duesseldorf,Germany)
GermanFederal Ministry of Health (Berlin, Germany)
German Diabetes Center (DDZ)
ProjektDEAL
DOI 10.1007/s00125-022-05846-8
WOS ID 000894587200001
WOS ID WOS:000894587200001
Scopus ID 85143495426
PubMed ID 36472640
Erfassungsdatum 2022-12-15
[➜Korrektur melden]